Catalyst Pharmaceuticals Names Dr. William T. Andrews, MD, FACP, As The New Chief Medical Officer

Catalyst Pharmaceuticals announced the appointment of Dr. William (Will) T. Andrews, MD, FACP, as its new Chief Medical Officer. In this role, Dr. Andrews will report directly to Richard J. Daly, the company’s President and Chief Executive Officer, and will become part of Catalyst’s executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a distinguished career. To ensure a smooth transition, Dr. Ingenito will remain with the company in a consulting capacity.

Dr. Andrews brings more than two decades of experience in the global biopharmaceutical industry, with a strong background in clinical development, medical affairs, corporate strategy, commercial planning, and business development. He has worked with both drugs and biologics across a range of therapeutic areas and has been involved in all stages of product development. His primary area of focus has been rare diseases, a field in which he has worked for the past 18 years.

Richard J. Daly, President and Chief Executive Officer, Catalyst, stated, “We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country’s most prestigious hospitals, he brings significant experience in biopharmaceuticals to this role. This is an exciting time to join Catalyst as we work to continue our exceptional financial performance that underscores the strength of our commercial strategy and the growing demand for our differentiated therapies that help patients live healthier lives. We would like to thank Dr. Gary Ingenito for his incredible service to Catalyst over the past ten years and congratulate him on his formidable career in the biopharmaceutical industry.”

Since 2023, Dr. Andrews has served as the President, CEO, and co-founder of Lighthouse Bio, a biopharmaceutical startup dedicated to acquiring rare disease assets with the goal of building new companies. Before founding Lighthouse Bio, he established Aletheia Lifesciences, a consultancy offering strategic, clinical, and medical guidance to biopharmaceutical companies. He has also served as Chief Medical Officer at several organizations, including Flexion Therapeutics, Akcea Therapeutics, and Acer Therapeutics, and has held various roles of increasing responsibility at other companies in the industry.

Dr. Andrews began his professional career in clinical medicine, practicing at Harvard Vanguard Medical Associates and Brigham and Women’s Hospital. He was also a member of the clinical faculty in Internal Medicine at Harvard Medical School. He earned his undergraduate degree in biology from Harvard University and his medical degree from Yale University School of Medicine.